The Use of Levothyroxine Absorption Tests in Clinical Practice
The Journal of Clinical Endocrinology & Metabolism · 14.07.2023 · 108 (8) · 1875-1888
DOI: 10.1210/clinem/dgad132 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 14.03.2023. Verfasst von Philippe Caron und 1 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Endocrinologie, Maladies Métaboliques et Nutrition, Pôle Cardio-Vasculaire et Métabolique, Hôpital Larrey, CHU de Toulouse, Toulouse F-3105…. Hauptthemen laut MEDLINE: Thyroxine, Hypothyroidism. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 85 Literaturangaben. Gefördert von: Merck, Merck KGaA.
Abstract (Originalsprache)
Although levothyroxine (LT4) is a widely prescribed drug, more than 30% of LT4-treated patients fail to achieve the recommended serum level of thyrotropin with a body weight–based dose of LT4. An LT4 absorption test (LT4AT) is part of the workup for confirming normal LT4 absorption or diagnosing malabsorption. We searched PubMed with the terms levothyrox*, L-T4, LT4, TT4, FT4, FT3, TT3, test, loading, uptake, absorp*, “absorb*, bioavailab*, bioequiv* malabsorb*, and pseudomalabsorb*. A total of 43 full-text publications were analyzed. The published procedures for LT4AT differ markedly in the test dose, formulation, test duration, frequency of blood collection, analyte (total thyroxine [TT4] or free thyroxine [FT4]), metric (absolute or relative peak or increment, or area under the curve) and the threshold for normal absorption. In a standardized LT4AT for routine use, the physician could advise the patient to not consume food, beverages, or medications the morning of the test; administer 1000 µg of LT4 in the patient's usual formulation as the test dose; ensure that the patient is supervised throughout the LT4AT; perform a 4-hour test, with hourly blood samples; assay FT4; and consider that normal LT4 absorption corresponds to an FT4 increment of more than 0.40 ng/dL (5.14 pmol/L) or a TT4 increment of more than 6 μg/dL (77.23 nmol/L) for a test dose of at least 300 µg, or a percentage TT4 absorption of more than 60%. If the test indicates abnormal LT4 absorption, the physician can increase the LT4 dose, change the formulation or administration route, and/or refer the patient to a gastroenterologist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service d'Endocrinologie, Maladies Métaboliques et Nutrition, Pôle Cardio-Vasculaire et Métabolique, Hôpital Larrey, CHU de Toulouse, Toulouse F-31059, France.
- Service de Biologie du Médicament-Toxicologie, Hôpital Cochin, AP-HP, Paris F-75006, France.
- INSERM UMR-S1144, Université Paris Cité, Paris F-75006, France.
ORCID-Profile: Philippe Caron, Xavier Declèves
Förderung
- Merck
- Merck KGaA
Zitieren
APA
Caron, P., & Declèves, X. (2023). The Use of Levothyroxine Absorption Tests in Clinical Practice. The Journal of Clinical Endocrinology & Metabolism, 108(8), 1875-1888. https://doi.org/10.1210/clinem/dgad132
Vancouver
Caron P, Declèves X. The Use of Levothyroxine Absorption Tests in Clinical Practice. The Journal of Clinical Endocrinology & Metabolism. 2023;108(8):1875-1888. doi:10.1210/clinem/dgad132
BibTeX
@article{Caron2023,
author = {Caron, Philippe and Declèves, Xavier},
title = {The Use of Levothyroxine Absorption Tests in Clinical Practice},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2023},
volume = {108},
number = {8},
pages = {1875--1888},
doi = {10.1210/clinem/dgad132}
}
EUVIMED